Mosaic Therapeutics

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential of the assets As part of the agreement Astex has taken an equity stake in Mosaic. 24 April 2025 -- Cambridge, UK -- Mosaic Therapeutics,...

Mosaic Therapeutics appoints Dr Barry Davies as CSO

Former AstraZeneca Senior Director, Global Project Leader adds significant experience and expertise to leadership team Appointment will drive further development of Mosaic’s targeted oncology combination therapies pipeline and platform. 7 October 2024 -- Cambridge UK -- Mosaic Therapeutics, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients,...

Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

Cambridge, UK, 04 April 2023 - Mosaic Therapeutics, Ltd, (ëMosaicí, or ëthe Companyí) an oncology therapeutics company dedicated to resolving cancerís complexity to power new treatments for patients, today announced the close of its $28 million series A funding round. The Company also announces the appointment of former Novartis Oncology SVP Brian Gladsden as CEO....
Mosaic Therapeutics Wellcome Genome Campus Cambridge CB10 1DR

+44 (0) 7787 502 947